Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents

Pharmacol Biochem Behav. 2010 Jun;95(4):449-56. doi: 10.1016/j.pbb.2010.03.006. Epub 2010 Mar 25.

Abstract

The present studies assessed the potential abuse liability and likely mechanism(s) of action of the wake-promoting agent modafinil.

Methods: Experiments assessed the locomotor sensitization (LS) and discriminative stimulus (DS) properties of modafinil in mouse and rat, respectively. Comparative data were generated with a range of psychostimulants and monoamine reuptake inhibitors.

Results: Repeated administration of d-amphetamine and cocaine, psychostimulants with high abuse liability, resulted in the induction and expression of LS in mice. Bupropion and caffeine, two psychostimulants not abused in humans, were not associated with LS. GBR12909 induced LS during repeated exposure, but there was no evidence of expression of LS after acute challenge following withdrawal. In contrast, repeated administration of modafinil resulted in the expression, but not induction, of LS. d-amphetamine, but not the mu-opioid agonist morphine or the nAChR agonist nicotine, fully substituted for the cocaine DS in rats. The selective dopamine transporter (DAT) inhibitor GBR12909 fully substituted, the preferential norepinephrine transporter (NET) inhibitor desipramine partially substituted, and the selective serotonin reuptake inhibitor citalopram failed to substitute for cocaine. Modafinil fully substituted for cocaine, similar to the mixed DAT/NET inhibitor bupropion.

Conclusions: Two preclinical assays indicated potential abuse liability of modafinil; drug discrimination studies suggest DAT blockade by modafinil is a likely mechanism of action in vivo.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Benzhydryl Compounds / adverse effects*
  • Benzhydryl Compounds / pharmacology*
  • Biogenic Monoamines / antagonists & inhibitors
  • Central Nervous System Stimulants / adverse effects
  • Central Nervous System Stimulants / pharmacology*
  • Cocaine / pharmacology
  • Dopamine Plasma Membrane Transport Proteins / antagonists & inhibitors
  • Dose-Response Relationship, Drug
  • Drug Evaluation, Preclinical / methods
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Modafinil
  • Motor Activity / drug effects*
  • Neurotransmitter Uptake Inhibitors / adverse effects
  • Neurotransmitter Uptake Inhibitors / pharmacology
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Substance Withdrawal Syndrome / physiopathology
  • Substance Withdrawal Syndrome / prevention & control
  • Substance-Related Disorders / physiopathology*
  • Substance-Related Disorders / prevention & control
  • Time Factors
  • Wakefulness / drug effects*

Substances

  • Benzhydryl Compounds
  • Biogenic Monoamines
  • Central Nervous System Stimulants
  • Dopamine Plasma Membrane Transport Proteins
  • Neurotransmitter Uptake Inhibitors
  • Cocaine
  • Modafinil